<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Ligand Pharmaceuticals Incorporated

    Ligand Pharmaceuticals Incorporated

    Ligand is a biopharmaceutical company focused on developing or acquiring technolog...

    Ligand is a biopharmaceutical company focused o...

    Filing Type:    PU
    Enlivex Therapeutics Ltd.

    Enlivex Therapeutics Ltd.

    Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug p...

    Enlivex is a clinical stage immunotherapy compa...

    Filing Type:    PU
    Immunic, Inc.

    Immunic, Inc.

    Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company develop...

    Immunic, Inc. (Nasdaq: IMUX) is a clinical-stag...

    Filing Type:    PU
    Livongo Health, Inc.

    Livongo Health, Inc.

    Livongo Health, Inc. (NASDAQ: LVGO) is a leading Applied Health Signals company em...

    Livongo Health, Inc. (NASDAQ: LVGO) is a leadin...

    Filing Type:    PU
    ZYPPAH, Inc.

    ZYPPAH, Inc.

    Stop the root cause of snoring by going directly after the tongue. ZYPPAH is the o...

    Stop the root cause of snoring by going directl...

    Amount Raised:    $359,340.00
    Fundraising Status:    EC
    Filing Type:    CF
    Cellular Biomedicine Group, Inc.

    Cellular Biomedicine Group, Inc.

    Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapie...

    Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)...

    Filing Type:    PU
    TCR2 Therapeutics Inc.

    TCR2 Therapeutics Inc.

    TCR² is an innovative immunotherapy company developing the next generation of T c...

    TCR² is an innovative immunotherapy company de...

    Filing Type:    PU
    BeyondSpring, Inc.

    BeyondSpring, Inc.

    Headquartered in New York, BeyondSpring Inc. (BeyondSpring) is a global, clinical-...

    Headquartered in New York, BeyondSpring Inc. (B...

    Filing Type:    PU
    NextCure, Inc.

    NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering an...

    NextCure is a clinical-stage biopharmaceutical ...

    Filing Type:    PU

    Predictive Oncology Inc.

    Predictive Oncology is a clinical and translational data pipeline and AI-driven pl...

    Predictive Oncology is a clinical and translati...

    Filing Type:    PU
    Compugen Ltd.

    Compugen Ltd.

    Compugen is a drug discovery company with a unique, broadly applicable, predictive...

    Compugen is a drug discovery company with a uni...

    Filing Type:    PU
    Agios Pharmaceuticals, Inc.

    Agios Pharmaceuticals, Inc.

    Agios is a biopharmaceutical company passionately committed to applying our scient...

    Agios is a biopharmaceutical company passionate...

    Filing Type:    PU
    ©2025 National Investor Network. All Rights Reserved.